Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 7896-7902

  Benderra, Zineb ^a   Faussat, Anne Marie ^a   Sayada, Lydia ^a   Perrot, Jean Yves ^a   Chaoui, Driss ^a   Marie, Jean Pierre ^a   Legrand, Ollivier ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; INTERCALATING AGENT; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; ORGANIZATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CELL PROLIFERATION; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MIDDLE AGED; MITOXANTRONE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE;

EID: 9744264044     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0795     Document Type: Article

References (40)

1. Baudard M, Beauchamp-Nicoud A, Delmer A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16 year period. Leukemia (Baltimore) 1999;13:1481-90.
2. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9.
3. Borg AG, Burgess R, Green LM, et al. Overexpression of lung resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998;103:1083-91.
4. Del Poeta G, Venditti A, Stasi R, et al. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leuk Res 1999;23:451-65.
5. Leith C, Kopecky K, Chen I, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood 1999;94:1086-99.
6. van der Kolk DM, de Vries EG, van Putten WJ, et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 2000;6:3205-14.
7. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000;85:711-21.
8. Legrand O, Perrot JY, Simonin G, Baudard M, Marie JP. JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood 2001;97:502-8.
9. Smeets ME, Raymakers RA, Vierwinden G, et al. Idarubicin DNA intercalation is reduced by MRP1 and not Pgp. Leukemia (Baltimore) 1999;13:1390-8.
10. The AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998;103:100-9.
11. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 1992;10:1103-11.
12. Zittoun R, Suciu S, De Witte T, et al. Comparison of three intercalating agents in induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic transplantation: preliminary results of the EORTC-GIMEMA AML-10 randomized trial. Blood 1999;94:658.
13. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58:5337-9.
14. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
15. Ross DD, Yang W, Abruzzo LV, et al. A typical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst (Bethesda) 1999;91: 429-33.
16. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000;113:2011-21.
17. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000;96:365-8.
18. Abbott BL, Colapietro AM, Barnes Y, et al. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002;100:4594-601.
19. Steinbach D, Sell W, Voigt A, et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia (Baltimore) 2002;16: 1443-7.
20. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia (Baltimore) 2002; 16:833-9.
21. van der Kolk DM, Vellenga E, Scheffer GL, et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 2002;99:3763-70.
22. Bennett JM, Catovsky D, Daniel MT, et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981;47:553-61.
23. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92: 2322-33.
24. Wittwer CT, Hermann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 1997;22:130-8.
25. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 1997;245:154-60.
26. Yoshinaga Y, Fujita S, Gotoh M, et al. Human lung cancer cell line producing hepatocyte growth factor/scatter factor. Jpn J Cancer Res 1992;83:1257-61.
27. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22: 7340-58.
28. Marie JP, Brophy NA, Ehsan MN, et al. Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. Br J Haematol 1992;81:145-52.
29. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie J-P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998;91:4480-8.
30. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie J-P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 1999;94:1046-56.
31. Kaplan EI, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
32. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc B 1972;34:187-220.
33. Marie J-P, Legrand O, Perrot J-Y, et al. Measuring multidrug resistance expression in human malignancies: elaboration of concensus recommendations. Semin Hematol 1997;34:63-71.
34. Legrand O, Zompi S, Perrot JY, et al. P-glycoprotein and multidrug resistance associated protein-1 in 132 acute myeloid leukemias according to FAB subtypes and cytogenetic risk groups. Haematologica 2004; 89:34-41.
35. Solary E, Witz B, Caillot D, et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996;88:1198-205.
36. Wattel E, Solary E, Hecquet B, et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein:results of a randomized study. Br J Haematol 1998;102: 1015-24.
37. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98:3212-20.
38. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-32.
39. Archimbaud E, Jehn U, Thomas X, et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia (Baltimore) 1999;13: 843-9.
40. Broxterman HJ, Sonneveld P, van Putten WLJ, et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia (Baltimore) 2000;14:1018-24.